Samsung Biologics assures half of Japanese Top 10 Pharmas as clients

Seoul [South Korea]:: Samsung Biologics Co accelerates its expansion in Japan, the world’s third largest pharmaceutical market. The South Korean company has signed contracts with half of Japan’s Top 10 pharmaceutical and biotech businesses, which rapidly strengthen its presence in the region, according to a Pulse report, the English service of the Maaeil Business newspaper Korea. “We have signed contracts with four of Japan’s Top 10 pharmaceutical companies and are in final talks with another,” Samsung Biologics report quoted on Biojapan 2025 John Rim on Thursday in Yokohama. “Biojapan is an important event for us. To expand our customer base from the Global Top 20 to the Top 40 pharmaceutical businesses, collaboration with Japanese firms is essential. That’s why we set up a Tokyo sales office and sent dedicated sales staff,” he added. Japan is third to the United States worldwide, with strong technological abilities in antibody conjugates and cell and gene therapies. With reference to research and markets, the Japan contract development market is expected to grow by 2030 at an annual rate of 6.8 percent from USD 12.3 billion in 2023 to USD 19.5 billion. “We focus on antibodies and ADC projects as we build confidence through face-to-face meetings.” “The company recently increased its annual revenue growth forecast from 20-25 percent to 25-30 percent, suggesting that this year’s revenue can be won about 6 trillion, from 4.55 trillion in 2024,” the report states. As for the possible expansion to the United States, RIM has maintained a cautious stance amid tariff assurances. “We are constantly reviewing possible entry into the US market, and the probability is higher than it was two to three years ago,” the report cited. “Since labor and construction costs in the US are more than 70 percent higher than in Korea, we will make decisions after carefully assessing the demand, rates and process efficiency.” Samsung Biologics recently launched Plant 5 to integrate automation and artificial intelligence technologies, strengthening the smart factory infrastructure. This article was generated from an automated news agency feed without edits to text.